Retrospective studies of stage IV NSCLC have reported that patients with low ERCC1 or RRM1 mRNA levels had a median survival up to 15 months when treated with gemcitabine plus cisplatin, with more significant differences in survival according to RRM1 levels[8], [9], [10]. This evidence concerns the gene RRM1 and non-small cell lung carcinoma.